Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
79.81
206.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Net Margin
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | CN |
| Market Cap | 12.6B CNY |
| Net Margin |
46%
|
| Country | JP |
| Market Cap | 6.8T JPY |
| Net Margin |
24%
|
| Country | CH |
| Market Cap | 37.9B CHF |
| Net Margin |
12%
|
| Country | DK |
| Market Cap | 200.9B DKK |
| Net Margin |
19%
|
| Country | US |
| Market Cap | 16.9B USD |
| Net Margin |
11%
|
| Country | KR |
| Market Cap | 9.9T KRW |
| Net Margin |
-358%
|
| Country | CA |
| Market Cap | 6.9B USD |
| Net Margin |
-8%
|
| Country | CN |
| Market Cap | 48.6B CNY |
| Net Margin |
42%
|
| Country | US |
| Market Cap | 6.3B USD |
| Net Margin |
29%
|
| Country | US |
| Market Cap | 6.1B USD |
| Net Margin |
9%
|
| Country | UK |
| Market Cap | 4.8B GBP |
| Net Margin |
7%
|
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Glance View
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, production, and sale of aortic and peripheral vascular interventional medical devices. The company is headquartered in Shanghai, Shanghai and currently employs 660 full-time employees. The company went IPO on 2019-07-22. The firm's main products include the aortic stent graft system for aortic minimally invasive interventional procedures, the intraoperative stent system for open surgery, as well as the peripheral vascular stent system and peripheral balloon dilatation catheters for the treatment of peripheral vascular diseases. The firm mainly distributes its products to the domestic market.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Shanghai MicroPort Endovascular MedTech Group Co Ltd's most recent financial statements, the company has Net Margin of 45.6%.
You don't have any saved screeners yet
